+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P03883(SLC1A2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P03883(SLC1A2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The SLC1A2 antibody targets the solute carrier family 1 member 2 (SLC1A2), a protein encoded by the SLC1A2 gene, also known as excitatory amino acid transporter 2 (EAAT2). This transmembrane protein is predominantly expressed in astrocytes within the central nervous system (CNS) and plays a critical role in regulating extracellular glutamate levels. By transporting glutamate—a major excitatory neurotransmitter—into glial cells, SLC1A2 prevents glutamate-induced neuronal excitotoxicity, maintaining synaptic plasticity and neural homeostasis. Dysregulation of SLC1A2 is implicated in neurodegenerative disorders (e.g., amyotrophic lateral sclerosis, Alzheimer’s disease), epilepsy, and psychiatric conditions.

The SLC1A2 antibody is widely used in neuroscience research to study protein expression, localization, and function in both healthy and diseased tissues. Applications include immunohistochemistry, Western blotting, and flow cytometry. Researchers rely on validated antibodies to ensure specificity, as cross-reactivity with other glutamate transporters (e.g., EAAT1 or EAAT3) may occur. Recent studies also explore SLC1A2’s role in neuroinflammation and its potential as a therapeutic target. However, variability in antibody performance across experimental conditions underscores the need for rigorous validation, including knockout controls, to confirm reliability in diverse models, from cell lines to post-mortem human brain samples.